HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

catumaxomab

Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular cytokine release induced by therapeutic antibodies
Networked: 65 relevant articles (15 outcomes, 27 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Lindhofer, Horst: 12 articles (06/2014 - 07/2007)
2. Bokemeyer, Carsten: 7 articles (10/2015 - 08/2010)
3. Jäger, Michael: 7 articles (06/2012 - 07/2007)
4. Wimberger, Pauline: 6 articles (12/2015 - 07/2007)
5. Sehouli, Jalid: 6 articles (09/2015 - 08/2009)
6. Seimetz, Diane: 6 articles (06/2014 - 03/2010)
7. Friccius-Quecke, Hilke: 5 articles (12/2014 - 10/2007)
8. Heiss, Markus M: 5 articles (06/2014 - 09/2010)
9. Ruf, Peter: 4 articles (12/2015 - 05/2010)
10. Pietzner, Klaus: 4 articles (12/2014 - 08/2011)

Related Diseases

1. Ascites
2. Neoplasms (Cancer)
3. Ovarian Neoplasms (Ovarian Cancer)
4. Carcinoma (Carcinomatosis)
5. Stomach Neoplasms (Stomach Cancer)

Related Drugs and Biologics

1. tumor-associated antigen GA733
2. Cytokines
3. Epidermal Growth Factor Receptor (EGF Receptor)
4. bevacizumab
5. cetuximab (Erbitux)
6. Platinum
7. Interleukin 1 Receptor Antagonist Protein (Anakinra)
8. Sirolimus (Rapamycin)
9. Succinic Acid (Succinate)
10. Teriparatide (Parathar)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Parenteral Infusions
3. Immunotherapy
4. Stents
5. Premedication